Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
abacavir + tenofovir
- Development stage
- Discontinued
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Abacavir + tenofovir is a combination of two nucleoside/nucleotide reverse transcriptase inhibitors used in HIV treatment. However, this specific combination is generally avoided in clinical practice due to high rates of treatment failure. Studies have reported excessive and rapid early treatment failure in regimens containing both abacavir and tenofovir. The combination can lead to the development of the K65R mutation in HIV-1 reverse transcriptase, which reduces phenotypic susceptibility to the drug combination.
- Brand names
- ZiagenViread
- Other names
- ABC + TDF
02
Targets
Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on abacavir + tenofovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on abacavir + tenofovir.